CapsoVision Inc Dossier - Source-backed chat

CapsoVision Inc

CVNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.00

Intrinsic Value $5.25median of 2 methodsbased on filings through 31 Mar 2026

Market Price $6.32Price as of 1 Oct 2026

OvervaluedIntrinsic value is 17% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $336.3M

Enterprise Value $319.1M

Shares Outstanding 50M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CapsoVision is a highly innovative, commercial-stage medical technology company pioneering wire-free, 360-degree panoramic capsule endoscopy. Unlike traditional axial-viewing systems (such as Medtronic's PillCam) that require patients to wear cumbersome external recording equipment, CapsoVision's flagship CapsoCam Plus stores high-resolution video directly on-board. This unique architecture enables a zero-capex, telehealth-friendly clinical workflow. Backed by a strong cash position of $17.9 million as of March 31, 2026, following a $14 million private placement, the company is approaching major inflection points. These include the mid-2026 FDA clearance of its in-house AI-assisted reading module and the Q3 2026 510(k) submission for its second-generation CapsoCam Colon capsule. Despite near-term gross margin headwinds from tariffs, CapsoVision's expanding clinical footprint (over 167,000 patients treated) and robust pipeline position it as a highly attractive, undervalued player in the growing $1.3 billion smart pills market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$10.00

High · most bullish analyst$10.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged regulatory delays for the AI-assisted reading module and the second-generation CapsoCam Colon. Continued tariff pressures and supply chain disruptions keep gross margins depressed below 48%, while elevated R&D spending on CMOS image sensors with Canon Inc. accelerates cash burn, requiring additional dilutive equity financing by mid-2027.

Base CaseCentral scenario

The base case assumes CapsoVision successfully secures FDA clearance for its AI-assisted reading feature in mid-2026, driving accelerated adoption and higher average selling prices (ASPs) in the second half of 2026. The second-generation CapsoCam Colon 510(k) is submitted in Q3 2026 as planned, with a commercial launch in late 2026 or early 2027. Revenue growth recovers to 15-20% annually, and gross margins stabilize around 50-52% as supply chain adjustments mitigate tariff impacts.

Bull CaseUpside scenario

CapsoVision's bull case is driven by strong commercial adoption of its wire-free, 360-degree panoramic CapsoCam Plus capsule (over 167,000 procedures completed), consistent year-over-year revenue growth since entering the U.S. market, and a clear pipeline expansion strategy. The upcoming commercial launch of its FDA-cleared AI-assisted reading module and the development of the second-generation CapsoCam Colon (with a planned 510(k) submission in Q3 2026) position the company to capture a significant share of the expanding gastrointestinal imaging market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated 360-degree panoramic lateral imaging technology that minimizes missed lesions compared to traditional single-camera axial systems.
Wire-free, zero-capex clinical workflow that eliminates patient-worn receiver equipment, enabling seamless remote/at-home ingestion.
Strong balance sheet with $17.9 million in cash as of March 31, 2026, providing a solid runway for pipeline execution.
Imminent regulatory catalysts, including the mid-2026 FDA clearance of the AI-assisted reading module and Q3 2026 CapsoCam Colon submission.

Key Investment Risks

High market concentration, with Medtronic holding a dominant share of the U.S. capsule endoscopy market.
Gross margin vulnerability to international trade policies and tariffs on Asian-sourced components.
Regulatory risks associated with FDA clearance timelines for the AI module and second-generation colon capsule.
Ongoing operating losses and cash burn from intensive R&D and clinical trial activities.

Thesis Invalidation Triggers

Failure to obtain FDA clearance for the AI-assisted reading feature by the end of 2026.
Significant delays in the 510(k) submission or clinical trial enrollment for the second-generation CapsoCam Colon.
Gross margins falling below 45% due to worsening tariff conditions or manufacturing inefficiencies.
Quarterly cash burn accelerating beyond $8 million, prematurely depleting the company's cash reserves.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.